476 related articles for article (PubMed ID: 35085851)
21. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
22. The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.
Moradi-Kalbolandi S; Majidzadeh-A K; Abdolvahab MH; Jalili N; Farahmand L
Probiotics Antimicrob Proteins; 2021 Oct; 13(5):1239-1253. PubMed ID: 33770348
[TBL] [Abstract][Full Text] [Related]
23. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques.
Xu F; Wu S; Yi L; Peng S; Wang F; Si W; Hou L; Zhu T
Emerg Microbes Infect; 2022 Dec; 11(1):438-441. PubMed ID: 35094672
[TBL] [Abstract][Full Text] [Related]
24. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.
Dhama K; Dhawan M; Tiwari R; Emran TB; Mitra S; Rabaan AA; Alhumaid S; Alawi ZA; Al Mutair A
Hum Vaccin Immunother; 2022 Nov; 18(5):2045853. PubMed ID: 35258416
[TBL] [Abstract][Full Text] [Related]
26. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
[TBL] [Abstract][Full Text] [Related]
27. Intranasal (IN) COVID-19 vaccines - a breakthrough.
Singh Gambhir R; Kaur K; Matariya R; Singh B; Sood R; Singh J
Rocz Panstw Zakl Hig; 2023; 74(1):15-18. PubMed ID: 37010354
[TBL] [Abstract][Full Text] [Related]
28. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
29. Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges.
Kar S; Devnath P; Emran TB; Tallei TE; Mitra S; Dhama K
Immun Inflamm Dis; 2022 Apr; 10(4):e604. PubMed ID: 35349752
[TBL] [Abstract][Full Text] [Related]
30. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
31. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
[TBL] [Abstract][Full Text] [Related]
32. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
33. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
Focosi D; Maggi F; Casadevall A
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
[TBL] [Abstract][Full Text] [Related]
34. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
[TBL] [Abstract][Full Text] [Related]
35. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H
Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873
[TBL] [Abstract][Full Text] [Related]
36. Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine.
Yeung J; Wang T; Shi PY
Curr Opin Virol; 2023 Oct; 62():101347. PubMed ID: 37604085
[TBL] [Abstract][Full Text] [Related]
37. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
Front Immunol; 2021; 12():729189. PubMed ID: 34603303
[TBL] [Abstract][Full Text] [Related]
38. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
[TBL] [Abstract][Full Text] [Related]
39. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
40. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
